World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
98
Citations
58560
World Ranking
8736
National Ranking
266

Mario Campone publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Mario Campone sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 780 publications — 86th percentile

86% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Mario Campone D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Mario Campone sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 98 D-Index — 57th percentile

57% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Mario Campone is affiliated with Grenoble Alpes University in France. Their research primarily spans the fields of Medicine and Biochemistry, Genetics and Molecular Biology, with a particular focus on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Molecular Biology, and Genetics.

Their main topics of research include:

  • Advanced Breast Cancer Therapies
  • HER2/EGFR in Cancer Research
  • Breast Cancer Treatment Studies
  • Cancer Treatment and Pharmacology
  • Cancer Genomics and Diagnostics
  • Glioma Diagnosis and Treatment
  • Radiomics and Machine Learning in Medical Imaging

Mario Campone has published research in numerous prominent venues. These frequent publication venues include:

  • Cancer Research
  • Annals of Oncology
  • Journal of Clinical Oncology
  • ESMO Open
  • Clinical Cancer Research

Some recent papers authored by Mario Campone cover a range of significant topics in cancer research and treatment:

  • Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study, 2020, The Lancet Oncology
  • Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1, 2020, Annals of Oncology
  • Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial, 2022, The Lancet Oncology
  • Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study, 2021, Annals of Oncology
  • Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial, 2020, The Lancet Oncology

Mario Campone frequently collaborates with several co-authors contributing substantially to their research output. These frequent co-authors include:

  • Fabrice André
  • Jean-Sébastien Frénel
  • Florence Dalenc
  • Paul Cottu
  • Pascal Jézéquel

Best Publications

  • Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer

    Charles E. Geyer;John Forster;Deborah Lindquist;Stephen Chan

  • Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

    José Baselga;Mario Campone;Martine Piccart;Howard A. Burris

  • Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer

    Sandra M. Swain;José Baselga;Sung-Bae Kim;Jungsil Ro

  • Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer

    Fabrice André;Eva Ciruelos;Gabor Rubovszky;Mario Campone

  • Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer

    Gabriel N. Hortobagyi;Salomon M. Stemmer;Howard A. Burris;Yoon-Sim Yap

  • MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer

    Matthew P. Goetz;Masakazu Toi;Mario Campone;Joohyuk Sohn

  • Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial

    Christophe Le Tourneau;Christophe Le Tourneau;Jean Pierre Delord;Anthony Gonçalves;Céline Gavoille

  • Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study

    Sandra M Swain;Sung-Bae Kim;Javier Cortés;Jungsil Ro

  • A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses

    David Cameron;Michelle Casey;Michael Press;Deborah Lindquist

  • Lomustine and Bevacizumab in Progressive Glioblastoma

    Wolfgang Wick;Thierry Gorlia;Martin Bendszus;Martin Taphoorn

  • Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor–Positive Breast Cancer

    José Baselga;Vladimir Semiglazov;Peter van Dam;Alexey Manikhas

  • Lapatinib Plus Capecitabine in Patients With Previously Untreated Brain Metastases From HER2-positive Metastatic Breast Cancer (LANDSCAPE): A Single-Group Phase 2 Study

    Thomas Bachelot;Gilles Romieu;Mario Campone;Véronique Diéras

  • Sequential Adjuvant Epirubicin-Based and Docetaxel Chemotherapy for Node-Positive Breast Cancer Patients: The FNCLCC PACS 01 Trial

    Henri Roché;Pierre Fumoleau;Marc Spielmann;Jean-Luc Canon

  • Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.

    Gabriel N. Hortobagyi;Salomon M. Stemmer;Howard A. Burris;Yoon-Sim Yap

  • A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer

    Pierre Farmer;Pierre Farmer;Pierre Farmer;Hervé Bonnefoi;Pascale Anderle;David Cameron;David Cameron

  • Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study.

    Sylvia Adams;Peter Schmid;Hope H.S. Rugo;Eric Winer

  • Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

    Sandra M Swain;Sandra M Swain;David Miles;Sung-Bae Kim;Young-Hyuck Im

  • Ixabepilone Plus Capecitabine for Metastatic Breast Cancer Progressing After Anthracycline and Taxane Treatment

    Eva S. Thomas;Henry L. Gomez;Rubi K. Li;Hyun Cheol Chung

  • Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2

    M. Piccart;G. N. Hortobagyi;M. Campone;K. I. Pritchard

  • Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034

    Martin J. van den Bent;Alba A. Brandes;Roy Rampling;Mathilde C.M. Kouwenhoven

Frequent Co-Authors

Fabrice Andre
Fabrice Andre Institut Gustave Roussy
Hope S. Rugo
Hope S. Rugo University of California, San Francisco
Véronique Diéras
Véronique Diéras Institute Curie
Pierfranco Conte
Pierfranco Conte University of Padua
Suzette Delaloge
Suzette Delaloge Institut Gustave Roussy
Patrice Viens
Patrice Viens Aix-Marseille University
Javier Cortes
Javier Cortes Vall d'Hebron Hospital Universitari
José Baselga
José Baselga Memorial Sloan Kettering Cancer Center
Ingrid A. Mayer
Ingrid A. Mayer Vanderbilt University Medical Center
Howard A. Burris
Howard A. Burris Sarah Cannon Research Institute

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring medicine in the USA opens doors to a diverse range of online degrees and career pathways in healthcare. For those seeking a quick entry into the field, fast track medical programs, such as LPN courses, allow you to start working sooner while gaining vital patient care experience.

Specialized careers are also within reach through online education. For example, psych np online programs prepare nurses to address mental health needs and are in high demand across various healthcare settings.

If your interests lie in healthcare leadership or administration, there are many affordable ways to advance. Pursue one of the cheapest mha programs online and gain essential skills for managing healthcare organizations. Alternatively, browse the cheapest mha online programs if you’re comparing master’s degrees with a cost-conscious approach.

Whether you’re starting or advancing your healthcare career, online programs offer flexible, accessible options to meet your professional goals.

Best Scientists Citing Mario Campone

Trending Scientists

Recently Published Articles